NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Medico Remedies Q2 FY27: Revenue Up 40.5% YoY to ₹73.97 Cr, Net Profit Dips 7.4% to ₹2.38 Cr
Medico Remedies reported standalone revenue from operations of ₹73.97 Cr for Q2 FY27 (quarter ended Sep 30, 2026), marking a 40.5% YoY rise from ₹52.64 Cr in Q2 FY26. However, net profit declined 7.4% YoY to ₹2.38 Cr compared to ₹2.57 Cr in the prior-year period, compressed by higher raw material costs of ₹65.82 Cr. For H1 FY27, revenue reached ₹143.37 Cr with a net profit of ₹4.90 Cr and basic EPS of ₹0.59. The board also approved the appointment of M/s V. J. Talati & Co. as Cost Auditors for FY 2026-27.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q2 FY27 financial results showing top-line expansion alongside margin compression, and appointed a new Cost Auditor for FY 2026-27.
ஏன் இது முக்கியம்Demonstrates robust export and domestic demand volume growth, but underscores profitability sensitivity to raw material input costs and moderate pricing power.
Q2 FY27 Revenue from operations: ₹73.97 கோடிQ2 FY27 Net Profit: ₹2.38 கோடிQ2 FY27 Cost of materials consumed: ₹65.82 கோடிH1 FY27 Operating cash flow: ₹4.33 கோடிQ2 FY27 Basic EPS: ₹0.29
📅 குறுகிய காலம்Stock reaction may be subdued as strong revenue growth is offset by net profit contraction.
📈 நீண்ட காலம்Structural growth depends on scaling formulations, entering new pharmerging geographies, and mitigating client and margin concentration risks.
⚠ அபாய எச்சரிக்கைகள்
Sharp increase in raw material costs eating into gross margins
High working capital lockup indicated by trade receivables increase of ₹38.42 Cr in H1
👀 கவனிக்க வேண்டியவை
Monitor whether the company can pass on high raw material costs to protect operating margins in upcoming quarters, as well as the working capital cycle given the significant increase in trade receivables.
Medico Remedies Limited reported a strong performance for Q1 FY27, with revenue from operations surging 81.4% YoY to ₹69.40 cr. Net profit grew 38.5% YoY to ₹2.52 cr, although margins appear slightly compressed compared to the top-line growth. A significant shift was observed in the sales mix, with domestic sales jumping to ₹26.34 cr from just ₹2.74 cr in the preceding quarter. The board also approved the re-appointment of key promoter-directors and an increase in the Managing Director's remuneration.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved record quarterly revenue and significantly diversified its geographical revenue base by increasing domestic market penetration.
ஏன் இது முக்கியம்The strong top-line growth validates the company's expansion strategy, though the shift toward domestic sales and increased management remuneration are key factors to watch for margin impact.
📅 குறுகிய காலம்The stock is likely to react positively to the substantial YoY revenue and profit growth reported for the June quarter.
📈 நீண்ட காலம்The structural shift toward domestic sales and the planned expansion into beta-lactam products could re-rate the business if execution remains consistent.
⚠ அபாய எச்சரிக்கைகள்
Significant shift in sales mix from exports to domestic
High customer concentration (top 5 historically 56%)
Increase in Managing Director remuneration
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the sudden surge in domestic sales and whether this shift from an export-heavy model (previously 95% exports) impacts long-term operating margins.
₹13.38 Cr Order Win: Medico Remedies to Supply Dominican Republic Government
Medico Remedies has secured a government supply order from PROMESE/CAL, Dominican Republic, valued at approximately ₹13.38 Crores (USD 1.41 million). The contract involves the supply of tablets, capsules, and dry syrups to the National Public Health System. The company is required to complete the entire order within a 3-month timeframe. This win is material, representing roughly 22.8% of the company's Dec 2025 quarterly revenue of ₹58.68 Crores.
உச்சம் நம்பிக்கை
என்ன மாறியதுMedico Remedies secured a new international government contract for pharmaceutical supplies in the Dominican Republic.
ஏன் இது முக்கியம்This order provides immediate revenue visibility and reinforces the company's strategy of expanding in pharmerging markets, leveraging its 95% export-oriented business model.
Order Value (INR): ₹13.38 CroresExecution Timeline: 3 மாதங்கள்Order vs Dec 2025 Revenue: ~22.8%Export Revenue Share: 95%Promoter Holding: 61.38%
📅 குறுகிய காலம்The stock may react positively to the order win, which represents a significant portion of quarterly turnover and provides a clear revenue catalyst for the next quarter.
📈 நீண்ட காலம்Continued success in international government tenders could lead to a more stable order book, though high customer concentration (top 5 = 56%) remains a structural risk to monitor.
⚠ அபாய எச்சரிக்கைகள்
Foreign exchange volatility (95% exports)
Tight 3-month execution timeline
High customer concentration (top 5 = 56% of revenue)
👀 கவனிக்க வேண்டியவை
Watch for the impact on the next two quarters' revenue and margins, especially considering the company's 95% export exposure and potential FX volatility during the 3-month execution period.
₹42 Cr Bank Facilities Rated; CRISIL Reaffirms BBB-/Stable for Medico Remedies
CRISIL Ratings has reaffirmed Medico Remedies Limited's long-term rating at 'CRISIL BBB-/Stable' and short-term rating at 'CRISIL A3'. Notably, the total rated bank facilities have been enhanced to ₹42 crore from the previous ₹19 crore, providing the company with additional credit headroom. With a current debt of ₹19 crore against a net worth of ₹76 crore (D/E of 0.25), the company maintains a conservative leverage profile. The enhancement in rated facilities likely supports the company's stated strategy to expand its manufacturing footprint and product range in export markets.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe total credit facilities rated by CRISIL have been increased from ₹19 crore to ₹42 crore, while the credit ratings themselves remain unchanged.
ஏன் இது முக்கியம்The reaffirmation of the 'Stable' outlook confirms the company's creditworthiness, while the increased limits provide the necessary liquidity to fund its planned expansion into beta-lactam products and new export regions.
Total Rated Facilities: ₹42 CrorePrevious Rated Amount: ₹19 CroreLong-term Rating: CRISIL BBB-/StableShort-term Rating: CRISIL A3Debt to Net Worth Ratio: 0.25
📅 குறுகிய காலம்The reaffirmation is expected to have a neutral impact on the stock price in the short term as it represents status quo on credit quality.
📈 நீண்ட காலம்The expanded credit limits support the company's long-term growth target of 11%, facilitating the production of new product ranges like Amoxicillin with potassium clavulanate.
⚠ அபாய எச்சரிக்கைகள்
High customer concentration (top 5 clients = 56% of revenue)
Potential liquidity strain if working capital cycle exceeds 200 GCA days
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization of the newly enhanced ₹42 crore credit limit and its impact on interest costs and the working capital cycle, particularly given the risk of GCA days stretching beyond 200 days.
Medico Remedies FY26 Net Profit Rises 30% to ₹13.13 Cr; Revenue Up 37% YoY
Medico Remedies Limited reported a robust financial performance for the fiscal year ended March 31, 2026. Annual revenue from operations grew significantly by 36.7% to ₹206.38 crore, while net profit increased by 30% to reach ₹13.13 crore. The fourth quarter (Q4 FY26) also showed strong momentum with a net profit of ₹5.86 crore compared to ₹4.34 crore in the corresponding quarter of the previous year. The company's auditors have issued a clean, unmodified opinion on these results.
முக்கிய அம்சங்கள்
Annual revenue from operations increased to ₹20,637.73 lakhs in FY26 from ₹15,094.06 lakhs in FY25.Net profit for the full year grew 30% YoY to ₹1,312.52 lakhs.Q4 FY26 revenue stood at ₹5,680.77 lakhs, representing a 37.5% growth over Q4 FY25.Earnings Per Share (EPS) improved to ₹1.58 for FY26 from ₹1.22 in the previous fiscal year.Total expenses for the year rose to ₹19,425.12 lakhs, driven largely by a 33% increase in material costs.
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's strong growth trajectory in both revenue and profitability. While the growth is impressive, monitoring the rising 'Other Expenses' and material costs will be crucial to ensure margin stability in future quarters.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Medico Remedies Approves Unaudited Financial Results for Q3 FY26
Medico Remedies Limited held a board meeting on February 12, 2026, to approve the unaudited standalone financial results for the quarter and period ended December 31, 2025. The meeting was conducted efficiently, lasting only 30 minutes from 5:00 PM to 5:30 PM. The board also reviewed and approved the Auditors' Limited Review Report for the same period. This filing marks the completion of the company's regulatory requirements for the third quarter of the 2025-26 fiscal year.
முக்கிய அம்சங்கள்
Board approved Unaudited Standalone Financial Results for the quarter ended December 31, 2025.The meeting was held on February 12, 2026, and concluded within 30 minutes.Auditors' Limited Review Report was formally considered and approved by the board.Compliance confirmed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables to evaluate revenue growth and margin performance compared to previous quarters. Monitor the stock for any price movement following the formal release of these earnings figures.
Medico Remedies Bags ₹37.18 Crore Order from UP Medical Supplies Corporation
Medico Remedies Limited has secured a significant domestic supply order worth approximately ₹37.18 crore from the Uttar Pradesh Medical Supplies Corporation Limited. The contract involves the supply of multiple drugs to the Government of Uttar Pradesh's centralized distribution entity. The company is expected to complete the full supply of the order by October 31, 2026. This government contract provides strong revenue visibility for the company over the next 20 months.
முக்கிய அம்சங்கள்
Total order value is ₹37,17,62,439 (approximately ₹37.18 crore)Contract awarded by Uttar Pradesh Medical Supplies Corporation Limited, a GoUP entityThe order involves the supply of multiple drugs for state-wide distributionProject completion timeline is set for October 31, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for revenue growth and monitor the company's ability to maintain margins on government-tendered contracts. Watch for timely execution updates as the October 2026 deadline approaches.
Medico Remedies Secures ₹73.23 Crore Order from UP Medical Supplies Corp
Medico Remedies Limited has bagged a significant domestic order worth ₹73.23 crore from the Uttar Pradesh Medical Supplies Corporation Limited, a Government of Uttar Pradesh entity. The contract involves the supply of Azithromycin 500mg tablets across the state's healthcare network. The company is mandated to complete the full supply of the order by October 31, 2026. This large-scale government contract provides strong revenue visibility and validates the company's standing in the pharmaceutical supply chain.
முக்கிய அம்சங்கள்
Total order value is approximately ₹73,23,16,646 for drug suppliesContract involves the supply of Azithromycin 500mg tablets to the UP GovernmentThe execution timeline for the full order is set until October 31, 2026The order is awarded by a domestic government entity with no promoter interest involved
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's order book and revenue growth. Monitor the company's ability to maintain margins while executing this large-scale government contract.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
